McGuireWoods partner Clint Narver speaks from experience: He joined the firm after serving in leadership roles at both agencies. With host Geoff Cockrell, Clint helps industry stakeholders understand regulators' enforcement priorities. He covers the responsibilities of clinical research organizations, the impact of decentralized clinical trials on regulatory oversight and the importance of corporate compliance in avoiding enforcement actions. He has also addressed these topics in a recent alert.
To investors looking at acquiring a company, Clint notes that DOJ's recent Mergers & Acquisitions Safe Harbor Policy is designed to incentivize the disclosure of corporate crime that is uncovered through the due diligence process.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
